COMMUNIQUÉS West-GlobeNewswire

EmpowerHER: A new professional network for female leaders in health launches
24/01/2024
OTTAWA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The EmpowerHER Leadership Network proudly unveils its innovative networking platform, marking a transformative milestone in championing and supporting women within Canadian [...]
KFSH&RC Celebrates 25 Scientists Named in Stanford's Top 2% Most-Cited Researchers Worldwide
24/01/2024
RIYADH, Saudi Arabia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them among the 'top 2% most- [...]
Fighting leprosy with artificial intelligence: DAHW and Belle.ai join forces with Senegal’s Ministry of Health and Social Action to detect and combat neglected diseases
24/01/2024
WÜRZBURG, Germany and CAMBRIDGE, Mass., Jan. 24, 2024 (GLOBE NEWSWIRE) -- DAHW German Leprosy and Tuberculosis Relief Association and BelleTorus Corporation (“Belle.ai”) have joined forces with Senegal’s Ministry of [...]
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
24/01/2024
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of Libmeldy® ( [...]
Coloplast Finance B.V. - Change of Auditor
24/01/2024
Today, 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting at which Ernst & Young Accountants LLP was elected as Coloplast Finance B.V.’s auditors. Attachment [...]
Coloplast Finance B.V. - Decisions at the Annual General Meeting
24/01/2024
On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2022/23. In addition, [...]
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
24/01/2024
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin (Molten Ventures) [...]
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24/01/2024
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First demonstration of efficacy in disease-relevant [...]
Sirona Biochem Corporate Update January 2024
24/01/2024
VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update [...]
Everest Group recognizes Indegene as a Leader in Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024
24/01/2024
PRINCETON, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Everest Group, a leading global research and consulting firm, has recognized Indegene as a Leader in its Life Sciences Digital Services Specialist PEAK Matrix ® [...]
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23/01/2024
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti- [...]
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
23/01/2024
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]
Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing
23/01/2024
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ” or “ VSAC ”), a special purpose acquisition company, announced today that it received a staff [...]
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
23/01/2024
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a [...]
STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024
23/01/2024
DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9: [...]
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
23/01/2024
Refinancing replaces prior senior credit facility MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and [...]
Intuitive Announces Fourth Quarter Earnings
23/01/2024
SUNNYVALE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Evaxion annonce l’entrée en vigueur de la Modification du Ratio d’ADS
23/01/2024
COPENHAGUE, Danemark, 23 janv. 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie spécialisée dans la recherche clinique et le développement de [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2023
23/01/2024
Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2023 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]

Pages